COMP <GO>
XRAY vs UNH // ENTERPRISE SCALE & MARKET CAP
DENTSPLY SIRONA Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: XRAY 2
— UNH 9
▲ ENTERPRISE SCALE & MARKET CAP LEADER: UNH
LAST: $9.61 (+1.80%) • MKT CAP: $1.92B
market-cap
$1.92B
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
market-cap
$368.83B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XRAY VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XRAY | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 50.00% | 88.57% | -38.57 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -11.00% | 11.47% | -22.47 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 12.27% | 6.48% | +5.79 | XRAY | /fcf-yield <GO> |
| Operating Margin | -11.50% | 4.82% | -16.32 | UNH | /operating-margins <GO> |
| Net Profit Margin | -16.20% | 3.14% | -19.34 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | -3.00% | 6.46% | -9.46 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 6.68% | 2.28% | +4.40 | XRAY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 3.12 | -2.67 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.5 | 59.2 | -2.70 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 17.7x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $1.92B | $368.83B | -$366.91B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XRAY REV | UNH REV | XRAY GROSS % | UNH GROSS % | XRAY FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.68B | $447.57B | 50.0% | 88.7% | $235.0M | $16.07B |
| FY 2024 | $3.79B | $400.28B | 51.6% | 88.3% | $461.0M | $20.70B |
| FY 2023 | $3.96B | $371.62B | — | 89.6% | $377.0M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XRAY // BETA —
UNH // BETA 0.33